Management and Prognosis of Patients with Recurrent or Persistent/Progressive Uterine Carcinosarcoma

Area of Science:

• Gynecologic Oncology
• Medical Malignancies
• Oncologic Surgery

Background:

• Uterine carcinosarcoma (UCS) is an aggressive gynecologic cancer with poor outcomes for recurrent or persistent disease.
• Effective management strategies for recurrent UCS are critical for improving patient prognosis.

Purpose of the Study:

• To investigate the management and prognostic factors for patients with recurrent or persistent/progressive uterine carcinosarcoma.
• To identify predictors of survival after recurrence (SAR) and cancer-specific survival (CSS).

Main Methods:

• Retrospective review of 168 UCS patients diagnosed between June 1987 and April 2020.
• Re-staging using the FIGO 2009 staging system.
• Univariate and multivariate analyses to determine predictors of SAR and CSS.

Main Results:

• 98 out of 168 patients experienced treatment failure, with a median time to treatment failure (TTF) of 8.1 months.
• Multivariate analysis indicated that salvage radiotherapy, chemotherapy, or chemoradiotherapy (CRT) significantly improved SAR.
• Disseminated recurrence was associated with significantly worse SAR, while surgery improved CSS but not SAR.

Conclusions:

• Salvage therapies including radiotherapy, chemotherapy, or CRT are associated with improved survival after recurrence in UCS patients.
• Surgery offers a survival benefit for cancer-specific survival (CSS) but not for SAR in UCS.
• Further research into optimal treatment paradigms for recurrent UCS is warranted.